Baillie Gifford & Co. Sells 363,734 Shares of Royalty Pharma PLC $RPRX

Baillie Gifford & Co. trimmed its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 2.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 17,008,768 shares of the biopharmaceutical company’s stock after selling 363,734 shares during the quarter. Baillie Gifford & Co. owned 2.95% of Royalty Pharma worth $657,219,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of the business. Financiere des Professionnels Fonds d investissement inc. acquired a new position in Royalty Pharma during the 3rd quarter worth approximately $933,000. Nordea Investment Management AB boosted its position in Royalty Pharma by 18.3% during the 3rd quarter. Nordea Investment Management AB now owns 775,999 shares of the biopharmaceutical company’s stock worth $27,137,000 after acquiring an additional 120,004 shares during the last quarter. World Investment Advisors acquired a new position in Royalty Pharma during the 3rd quarter worth approximately $1,702,000. Generali Asset Management SPA SGR boosted its position in Royalty Pharma by 7,752.8% during the 3rd quarter. Generali Asset Management SPA SGR now owns 34,081 shares of the biopharmaceutical company’s stock worth $1,202,000 after acquiring an additional 33,647 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Royalty Pharma by 28.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 140,131 shares of the biopharmaceutical company’s stock worth $4,944,000 after acquiring an additional 31,045 shares during the last quarter. 54.35% of the stock is owned by institutional investors.

Insider Activity at Royalty Pharma

In other Royalty Pharma news, CFO Terrance P. Coyne sold 34,791 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $48.33, for a total transaction of $1,681,449.03. Following the completion of the sale, the chief financial officer owned 32,916 shares of the company’s stock, valued at $1,590,830.28. This trade represents a 51.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 20,000 shares of the firm’s stock in a transaction on Friday, January 30th. The shares were sold at an average price of $41.09, for a total value of $821,800.00. The SEC filing for this sale provides additional information. In the last three months, insiders sold 477,496 shares of company stock valued at $20,408,425. 18.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on RPRX shares. Citigroup upped their price target on Royalty Pharma from $48.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, January 27th. UBS Group raised Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 price target for the company in a research report on Friday, January 30th. Weiss Ratings raised Royalty Pharma from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, February 12th. Morgan Stanley upped their price target on Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of Royalty Pharma in a research report on Thursday, February 12th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $49.00.

Royalty Pharma Trading Up 0.0%

NASDAQ RPRX opened at $47.91 on Monday. The company has a market cap of $27.64 billion, a PE ratio of 35.49, a PEG ratio of 3.06 and a beta of 0.39. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.88. Royalty Pharma PLC has a 12 month low of $30.96 and a 12 month high of $49.06. The stock has a 50 day moving average of $45.92 and a 200-day moving average of $41.12.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.33 by $0.13. The company had revenue of $621.99 million during the quarter, compared to the consensus estimate of $839.97 million. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%. On average, equities research analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.